Anza Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Anza Therapeutics sits in the upper quartile of US sponsors by registered trial count (#3,663 of 15,742 sponsors by registered trial count).

3 total trials none currently recruiting 1 completed early-phase tilt upper quartile by trial count

Anza Therapeutics: 3 sponsored US clinical trials, none currently recruiting.

Anza Therapeutics sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Liver Neoplasms, with 1 trials.

Upper-quartile sponsor footprint

Anza Therapeutics sits in the upper quartile of the sponsor corpus (#3,663 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

How the Anza Therapeutics early-phase archive is shaped

3 indexed studies, none listed as recruiting (0% open); 1 completed (33%).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Liver Neoplasms (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Anza Therapeutics: archived-pipeline peers nationwide

Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Anza Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-07-11 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Anza Therapeutics10xBio22nd Century GroupAA SecordAAADRS Clinical Research Center23andMe3-C Institute for Social Development3 Waves Wellness3EO Health
Anza Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-07-11 snapshot).

Anza Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Anza Therapeutics page

3 registered trials is a research-attention snapshot, not an endorsement of Anza Therapeutics or any single study.

  • None of Anza Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Liver Neoplasms is the condition Anza Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Liver Neoplasms trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Anza Therapeutics pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.